Were Helen Torley’s Halozyme (HALO) share dispositions open-market sales?

The filing states the dispositions of 11,334, 9,104, and 27,605 Halozyme shares were withheld by the issuer for tax obligations. This means the shares were not sold in the open market, but surrendered back to cover required withholding taxes.

Form 4: Torley Helen reports multiple insider transactions in HALO

Filing Impact

(Very High)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Torley Helen reported multiple insider transaction types in a Form 4 filing for HALO. The filing lists transactions totaling 226,153 shares at a weighted average price of $79.44 per share. Following the reported transactions, holdings were 16,874 shares.

Insider Trade Summary

89,055 shares exercised/converted

Mixed 9 txns

Insider Torley Helen

Role PRESIDENT AND CEO

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	21,009	$0.00	--
Exercise	Restricted Stock Units	16,875	$0.00	--
Exercise	Performance Stock Units	51,171	$0.00	--
Exercise	Common Stock	21,009	$0.00	--
Tax Withholding	Common Stock	11,334	$79.44	$900K
Exercise	Common Stock	16,875	$0.00	--
Tax Withholding	Common Stock	9,104	$79.44	$723K
Exercise	Common Stock	51,171	$0.00	--
Tax Withholding	Common Stock	27,605	$79.44	$2.19M

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Performance Stock Units — 0 shares (Direct); Common Stock — 729,728 shares (Direct)

Footnotes (1)

The reported disposition of 11,334 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. The reported disposition of 9,104 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. The reported disposition of 27,605 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer.

Form 4 Insider Transactions: What Each Field Means →

02/17/2026 - 06:51 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Torley Helen

(Last)

(First)

(Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO

92130

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/16/2026		M		21,009	A	$0	729,728	D
Common Stock	02/16/2026		F		11,334⁽¹⁾	D	$79.44	718,394	D
Common Stock	02/16/2026		M		16,875	A	$0	735,269	D
Common Stock	02/16/2026		F		9,104⁽²⁾	D	$79.44	726,165	D
Common Stock	02/16/2026		M		51,171	A	$0	777,336	D
Common Stock	02/16/2026		F		27,605⁽³⁾	D	$79.44	749,731	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0	02/16/2026		M			21,009	⁽⁴⁾	⁽⁴⁾	Common Stock	21,009	$0	0	D
Restricted Stock Units	$0	02/16/2026		M			16,875	⁽⁴⁾	⁽⁴⁾	Common Stock	16,875	$0	16,874	D
Performance Stock Units	$0	02/16/2026		M			51,171	⁽⁵⁾	⁽⁵⁾	Common Stock	51,171	$0	0	D

Explanation of Responses:

1. The reported disposition of 11,334 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.

2. The reported disposition of 9,104 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.

3. The reported disposition of 27,605 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.

4. This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

5. This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Halozyme (HALO) CEO Helen Torley report?

Helen Torley reported vesting of restricted and performance stock units that converted into Halozyme common stock. She also reported share dispositions used to cover tax withholding, with the issuer withholding shares rather than selling them on the open market.

How many Halozyme (HALO) shares did Helen Torley acquire through equity award vesting?

Equity awards covering 21,009 and 16,875 restricted stock units and 51,171 performance stock units converted into Halozyme common shares at $0 exercise price. These conversions reflect previously granted compensation becoming actual share ownership on the reported transaction date.

At what price were Halozyme (HALO) shares withheld for Helen Torley’s taxes?

The shares withheld to cover Helen Torley’s tax obligations were valued at $79.44 per Halozyme share. These tax-withholding dispositions satisfy required taxes triggered by the vesting and settlement of her restricted stock units and performance stock units.

How many Halozyme (HALO) shares does Helen Torley own after these transactions?

Following the reported transactions, Helen Torley directly beneficially owned 749,731 Halozyme common shares. She also held 16,874 restricted stock units, which represent a right to receive additional common shares in the future under the company’s equity compensation programs.

What types of equity awards vested for Halozyme (HALO) CEO Helen Torley?

The filing shows vesting and settlement of restricted stock units and performance stock units into Halozyme common shares. Restricted stock units vest over time, while performance stock units vest based on performance conditions, turning into actual share ownership when those conditions and vesting dates are met.